Senores Pharmaceuticals reported Q4FY26 total income of ₹190 crore, up 66% YoY, while PAT surged 104% YoY to ₹37 crore. FY26 total income increased 65% to ₹664 crore and PAT jumped 108%. The company expanded its regulated markets portfolio to 51 approved ANDAs and completed acquisition of stake in Apnar Pharmaceuticals.